Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3488-3499

  Masiakos, Peter T ^a   MacLaughlin, David T ^a   Maheswaran, Shyamala ^a   Teixeira, Jose ^a   Fuller Jr , Arlan F ^a   Shah, Paresh C ^a   Kehas, David J ^a   Kenneally, Mary K ^a   Dombkowski, David M ^a   Ha, Thanh U ^a   Preffer, Frederic I ^a   Donahoe, Patricia K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MUELLERIAN INHIBITING FACTOR; MUELLERIAN INHIBITING FACTOR 2 RECEPTOR; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; CELL ISOLATION; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DRUG BINDING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ANIMALS; ASCITES; CELL DIVISION; COS CELLS; CYSTADENOCARCINOMA; FEMALE; FETUS; GLYCOPROTEINS; GROWTH INHIBITORS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULLERIAN DUCTS; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; RATS; RECEPTORS, PEPTIDE; RECOMBINANT PROTEINS; TESTICULAR HORMONES; TESTIS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032753468     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Scully, R. Recent progress in ovarian cancer. Hum. Pathol., 1: 73-98, 1970.
2. Scully, R. Pathology of ovarian cancer precursors. J. Cell. Biochem. Suppl., 23: 208-218, 1995.
3. Hudson, P. L., Dougas, I., Donahoe, P. K., Cate, R. L., Epstein, J., Pepinsky, R. B., and MacLaughlin, DT. An immunoassay to detect human Mullerian inhibiting substance in males and females during normal development. J. Clin. Endocrinol. Metab., 70: 16-22, 1990.
4. Baker, M. L., Metcalfe, S. A., and Hutson, J. M. Serum levels of Mullerian inhibiting substance in boys from birth to 18 years as determined by enzyme immunoassay. J. Clin. Endocrinol. Metab., 70: 11-15, 1990.
5. Josso, N., Legeai, L., Forest, M. G., Chaussain, J. L., and Brauner, R. An enzyme linked immunoassay for anti-Mullerian hormone: a new tool for the evaluation of testicular function in infants and children. J. Clin. Endocrinol. Metab., 70: 23-17, 1990.
6. Lee, M. M., Donahoe, P. K., Hasegawa, T., Silverman, B., Crist, G. B., Best, S., Hasegawa, Y., Noto, R. A., Schoenfeld, D., and MacLaughlin, D. T. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J. Clin. Endocrinol. Metab., 81: 571-576, 1996.
7. Hirobe, S., He, W. W., Gustafson, M. L., MacLaughlin, D. T., and Donahoe, P. K. Mullerian inhibiting substance gene expression in the cycling rat ovary correlates with recruited or graafian follicle selection. Biol. Reprod., 50: 1238-1243, 1994.
8. Takahashi, M., Hayashi, M., Manganaro, T. F., and Donahoe, P. K. The ontogeny of Mullerian inhibiting substance in granulosa cells of the bovine ovarian follicle. Biol. Reprod., 35: 447-453, 1986.
9. Bezard, J., Vigier, B., Tran, D., Mauleon, P., and Josso, N. Immunocytochemical study of anti-Mullerian hormone in sheep ovarian follicles during fetal and post-natal development. J. Reprod. Fertil., 80: 509-516, 1987.
10. Ueno, S., Manganaro, T. F., and Donahoe, P. K. Human recombinant Mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro. Endocrinology, 123: 1652-1659, 1988.
11. Kim, J. H., Seibel, M. M., MacLaughlin, D. T., Donahoe, P. K., Ransil, B. J., Hametz, P. A., and Richard, C. J. The inhibitory effects of Mullerian-inhibiting substance on epidermal growth factor induced proliferation and progesterone production of human granulosa-luteal cells. J. Clin. Endocrinol. Metab., 75: 911-917, 1992.
12. Racine, C., Rey, R., Forest, M. G., Louis, F., Ferre, A., Huhtaniemi, I., Josso, N., and di Clemente, N. Receptors for anti-Mullerian hormone on Leydig cells are responsible for its effects on steroidogenesis and cell differentiation. Proc. Natl. Acad. Sci. USA, 95: 594-599, 1998.
13. Rouiller-Fabre, V., Carmon, S., Merhi, R. A., Cate, R., Habert, R., and Vigier, B. Effect of anti-Mullerian hormone on Sertoli and Leydig cell functions in fetal and immature rats. Endocrinology, 139: 1213-1220, 1998.
14. Teixeira, T., Fynn-Thompson, E., Payne, A. H., and Donahoe, P. K. Mullerian inhibiting substance regulates androgen synthesis at the transcriptional level. Endocrinology, 140: 4732-4738, 1999.
15. Baarends, W. M., van Helmond, M. J., Post, M., van der Schoot, P. J., Hoogerbrugge, J. W., de Winter, J. P., Uilenbroek, J. T., Karels, B., Wilming, L. G., Meijers, J. H., Themmen, A. P. N., and Grootegoed, J. A. A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the Mullerian duct. Development (Camb.), 120: 189-197, 1994.
16. di Clemente, N., Wilson, C., Faure, E., Boussin, L., Carmillo, P., Tizard, R., Picard, J. Y., Vigier, B., Josso, N., and Cate, R. Cloning, expression, and alternative splicing of the receptor for anti-Mullerian hormone. Mol. Endocrinol., 8: 1006-1020, 1994.
17. Imbeaud, S., Faure, E., Lamarre, I., Mattei, M. G., di Clemente, N., Tizard, R., Carre-Eusebe, D., Belville, C., Tragethon, L., Tonkin, C., Nelson, J., McAuliffe, M., Bidart, J. M., Lababidi, A., Josso, N., Cate, R. L., and Picard, J. Y. Insensitivity to anti-Mullerian hormone due to a mutation in the human anti-Mullerian hormone receptor. Nat. Genet., 11: 382-388, 1995.
18. Teixeira, J., He, W. W., Shah, P. C., Morikawa, N., Lee, M. M., Catlin, E. A., Hudson, P. L., Wing, J., MacLaughlin, D. T., and Donahoe, P. K. Developmental expression of a candidate Mullerian inhibiting substance type II receptor. Endocrinology, 137: 160-165, 1996.
19. He, W. W., Gustafson, M., Hirobe, S., and Donahoe, P. K. Developmental expression of four novel serine/threonine kinase receptors homologous to the activin/transforming growth factor-β type II receptor family. Dev. Dyn., 196: 133-142, 1993.
20. Behringer, R. R., Finegold, M. J., and Cate, R. L. Mullerian-inhibiting substance function during mammalian sexual development. Cell, 79: 415-425, 1994.
21. Mishina, Y., Rey, R., Finegold, M. J., Matzuk, M. M., Josso, N., Cate, R. L., and Behringer, R. R. Genetic analysis of the Mullerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev., 10: 2577-2587, 1996.
22. Behringer, R. R., Cate, R. L., Froelick, G. J., Palmiter, R. D., and Brinster, R. L. Abnormal sexual development in transgenic mice chronically expressing Mullerian inhibiting substance [see comments]. Nature (Lond.), 345: 167-170, 1990.
23. Ragin, R. C., Donahoe, P. K., Kenneally, M. K., Ahmad, M. F., and MacLaughlin, D. T. Human Mullerian inhibiting substance: enhanced purification imparts biochemical stability and restores antiproliferative effects. Protein Expression Purif., 3: 236-245, 1992.
24. MacLaughlin, D. T., Epstein, J., and Donahoe, P. K. Bioassay, purification, cloning, and expression of Mullerian inhibiting substance. Methods Enzymol., 198: 358-369, 1991.
25. MacLaughlin, D. T., Hudson, P. L., Graciano, A. L., Kenneally, M. K., Ragin, R. C., Manganaro, T. F., and Donahoe, P. K. Mullerian duct regression and antiproliferative bioactivities of Mullerian inhibiting substance reside in its carboxy-terminal domain. Endocrinology, 131: 291-296, 1992.
26. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
27. Donahoe, P. K., Ito, Y., and Hendren, W. H. A graded organ culture assay for the detection of Mullerian inhibiting substance. J. Surg. Res., 23: 141-148, 1977.
28. Boveri, J., Parry, R., Ruffin, W., Gustafson, M., Lee, K., He, W., and Donahoe, P. K. Transfection of the Mullerian inhibiting substance gene inhibits local and metastatic tumor growth. Int. J. Oncol., 2: 135-144, 1993.
29. Hamburger, A., and Salmon, S. Primary bioassay of human tumor stem cells. Science (Washington DC), 197: 461-466, 1977.
30. Fuller, A. F., Guy, S., Budzik, G. P., and Donahoe, P. K. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. J. Clin. Endocrinol. Metab., 54: 1051-1055, 1985.
31. Chin, T., Parry, R. L., and Donahoe, P. K. Human Mullerian inhibiting substance inhibits tumor growth in vitro and in vivo. Cancer Res., 51: 2101-2106, 1991.
32. Wallen, J. W., Cate, R. L., Kiefer, D. M., Riemen, M. W., Martinez, D., Hoffman, R. M., Von Hoff, D. D., Donahoe, P. K., Pepinsky, R. B., and Oliff, A. Minimal anti-proliferative effect of recombinant Mullerian inhibiting substance on gynecological tumor cell lines and tumor explants. Cancer Res., 49: 2005-2011, 1989.
33. Kurian, M. S., Sainz de la Cuesta, R., Waneck, G. L., MacLaughlin, D. T., Manganaro, T. F., and Donahoe, P. K. Cleavage of Mullerian inhibiting substance activates antiproliferative effects in vivo. Clin. Cancer Res., 1: 343-349, 1995.
34. Sambrook, J., Fritsch, F. H., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, pp. 7.3-7.84, 1989.
35. Sanger, F., Niklen, S., and Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
36. Takahashi, M., Koide, S. S., and Donahoe, P. K. Mullerian inhibiting substance as oocyte meiosis inhibitor. Mol. Cell. Endocrinol., 47: 225-234, 1986.
37. Kuroda, T., Lee, M. M., Haqq, C. M., Powell, D. M., Manganaro, T. F., and Donahoe, P. K. Mullerian inhibiting substance ontogeny and its modulation by follicle-stimulating hormone in the rat testes. Endocrinology, 127: 1825-1832, 1990.
38. Green, N. M. A spectrophotometric assay for avidin and biotin based on binding of dyes by avidin. Biochem. J., 23c-24c, 1965.
39. Parry, R. L., Chin, T. W., Epstein, J., Hudson, P. L., Powell, D. M., and Donahoe, P. K. Recombinant human Mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo. Cancer Res., 52: 1182-1186, 1992.
40. Lin, H. Y., Wang, X. F., NG-Eaton, E., Weinberg, R. A., and Lodish, H. F. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell, 68: 775-785, 1992.
41. Mathews, L. S., and Vale, W. W. Expression cloning of an activin receptor, a predicted transmembrane serine kinase. Cell, 65: 973-982, 1991.
42. Donahoe, P. K., Swann, D. A., Hayashi, A., and Sullivan, M. D. Mullerian duct regression in the embryo correlated with cytotoxic activity against human ovarian cancer. Science (Washington DC), 205: 913-915, 1979.
43. Ueno, S., Takahashi, M., Manganaro, T. F., Ragin, R. C., and Donahoe, P. K. Cellular localization of Mullerian inhibiting substance in the developing rat ovary. Endocrinology, 124: 1000-1006, 1989.
44. Yaginuma, Y., Hayashi, H., Kawai, K., Kurakane, T., Saitoh, Y., Kitamura, S., Sengoku, K., and Ishikawa, M. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p16INK4B) in human ovarian carcinoma cell lines. Exp. Cell Res., 233: 233-239, 1997.
45. Attisano, L., Carcamo, J., Ventura, F., Weis, F. M., Massagué, J., and Wrana, J. L. Identification of human activin and TGF β type I receptors that form heteromeric kinase complexes with type II receptors. Cell, 75: 671-680, 1993.
46. Ten Dijke, P., Yamashita, H., Ichijo, H., Franzen, P., Laiho, M., Miyazono, K., and Heldin, C. Characterization of type I receptors for transforming growth factor-β and activin. Science (Washington DC), 264: 101-104, 1994.
47. Ebner, R., Chen, R. H., Lawler, S., Zioncheck, T., and Derynck, R. Determination of type I receptor specificity by the type II receptors for TGF-β or activin. Science (Washington DC), 262: 900-902, 1993.
48. Valavaara, R. Reliability of estrogen receptors in predicting response to antiestrogens. Oncology (Huntingt.) Suppl., 4: 14-18, 1997.